Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines (Retraction of vol 79, pg 1367, 2005)

被引：0
|
作者：
Matsuda, Takehiro [1 ]
Almasan, Alex
Tomita, Mariko
Uchihara, Jun-Nosuke
Masuda, Masato
Ohshiro, Kazuiku
Takasu, Nobuyuki
Yagita, Hideo
Ohta, Takao
Mori, Naoki
机构：
[1] Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Fac Med, Nishihara, Okinawa 90301, Japan
来源：
JOURNAL OF VIROLOGY | 2011年 / 85卷 / 03期
关键词：
D O I：
10.1128/JVI.02070-10
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：1416 / 1416
页数：1
相关论文
共 50 条
  • [1] RETRACTED: Resistance to apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines (Retracted Article. See vol 85, pg 1416, 2011)
    Matsuda, T
    Almasan, A
    Tomita, M
    Uchihara, J
    Masuda, M
    Ohshiro, K
    Takasu, N
    Yagita, H
    Ohta, T
    Mori, N
    JOURNAL OF VIROLOGY, 2005, 79 (03) : 1367 - 1378
  • [2] Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L
    Di Pietro, R
    Zauli, G
    JOURNAL OF CELLULAR PHYSIOLOGY, 2004, 201 (03) : 331 - 340
  • [3] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity
    Fukuda, M
    Hamao, A
    Tanaka, A
    Kitada, M
    Suzuki, S
    Kusama, K
    Sakashita, H
    ONCOLOGY REPORTS, 2003, 10 (05) : 1113 - 1119
  • [4] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity
    Fukuda, M
    Tanaka, A
    Hamao, A
    Fukuda, F
    Kitada, M
    Suzuki, S
    Sakashita, H
    Kusama, K
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 339 - 340
  • [5] Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma
    Yamashita, YI
    Shimada, M
    Tanaka, S
    Okamamoto, M
    Miyazaki, JI
    Sugimachi, K
    HUMAN GENE THERAPY, 2002, 13 (02) : 275 - 286
  • [6] Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice
    Sedger, LM
    Glaccum, MB
    Schuh, JCL
    Kanaly, ST
    Williamson, E
    Kayagaki, N
    Yun, T
    Smolak, P
    Le, T
    Goodwin, R
    Gliniak, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2002, 32 (08) : 2246 - 2254
  • [7] The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and genistein is effective in inhibiting pancreatic cancer growth
    Nozawa, F
    Itami, A
    Saruc, M
    Kim, M
    Standop, J
    Picha, TS
    Cowan, KH
    Pour, PM
    PANCREAS, 2004, 29 (01) : 45 - 52
  • [8] Acute myeloid leukemia cells are resistant to tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a mechanism independent of multidrug resistance.
    Fricke, SM
    Minderman, H
    O'Loughlin, KL
    Cheng, JR
    Repasky, EA
    Baer, MR
    BLOOD, 2004, 104 (11) : 180B - 180B
  • [9] Study of the crystal shape and its influence on the anti-tumor activity of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL)
    Yin, Ji-Cheng
    Zhou, Jin-Song
    Suh, Jing
    Qiu, Yi
    Wei, Dong-Zhi
    Shen, Ya-Ling
    CRYSTAL RESEARCH AND TECHNOLOGY, 2008, 43 (08) : 888 - 893
  • [10] Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
    Poulaki, V
    Mitsiades, CS
    Kotoula, V
    Tseleni-Balafouta, S
    Ashkenazi, A
    Koutras, DA
    Mitsiades, N
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (02): : 643 - 654
12345